Baidu
map

上海中医药国际论坛,精彩视频集锦,阐述中医药未来发展趋势

2016-01-12 MedSci MedSci原创

中医药是我国独特的卫生资源、优秀的文化资源、有原创优势的科技资源、潜力巨大的经济资源、重要的生态资源。“上海中医药国际论坛”立足中国传统中医药学,发展现代中医科学,注重跨文化沟通与中医药服务贸易发展,邀请国内外医药领域权威专家做学术报告,旨在弘扬学术精神,推动中医药的国际传播,加速中医学科发展与多学科的交叉融合,促进学术研究与社会、经济生活的联系,为人们享有更健康美好的生活而努力。 上海中医

中医药是我国独特的卫生资源、优秀的文化资源、有原创优势的科技资源、潜力巨大的经济资源、重要的生态资源。“上海中医药国际论坛”立足中国传统中医药学,发展现代中医科学,注重跨文化沟通与中医药服务贸易发展,邀请国内外医药领域权威专家做学术报告,旨在弘扬学术精神,推动中医药的国际传播,加速中医学科发展与多学科的交叉融合,促进学术研究与社会、经济生活的联系,为人们享有更健康美好的生活而努力。

上海中医药国际论坛以“中医药临床研究•国际化进程”为主旨,培育和打造成一个高水准、具有国际影响力的中医药学术交流的平台和窗口。


主要演讲嘉宾包括:上海中医药学会王文健教授、上海中医药大学陈凯先院士、上海中医药大学施建蓉教授、上海中医药大学严世芸教授、美国Emory大学蔡 晖教授、国家药理学会林志彬教授、上海中医药学会陈军力教授、上海中医药大学王庆其教授、上海中医药学会陆金根教授、上海市中医药研究院中医药国际标准化研究所桑珍 教授、英国邓迪大学Geo A Corner 教授、华东理工大学颜建军 副教授等。精彩视频请下载:MedSci医学APP查看


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897666, encodeId=ff6f189e66612, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 10 02:13:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58027, encodeId=04555802ef2, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:12:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408718, encodeId=dade1408e18a3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 14 02:13:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56950, encodeId=331d56950c9, content=为什么点进去说是没有相关资源呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cb41604567, createdName=yz115, createdTime=Wed Jan 13 16:49:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56533, encodeId=681356533da, content=学习……, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90511609422, createdName=lindaliu, createdTime=Wed Jan 13 07:32:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56511, encodeId=224a56511b3, content=为什么点不进去, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 13 00:29:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56418, encodeId=21b556418df, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jan 12 16:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56406, encodeId=222756406b7, content=发展优势, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 12 14:35:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897666, encodeId=ff6f189e66612, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 10 02:13:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58027, encodeId=04555802ef2, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:12:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408718, encodeId=dade1408e18a3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 14 02:13:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56950, encodeId=331d56950c9, content=为什么点进去说是没有相关资源呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cb41604567, createdName=yz115, createdTime=Wed Jan 13 16:49:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56533, encodeId=681356533da, content=学习……, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90511609422, createdName=lindaliu, createdTime=Wed Jan 13 07:32:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56511, encodeId=224a56511b3, content=为什么点不进去, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 13 00:29:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56418, encodeId=21b556418df, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jan 12 16:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56406, encodeId=222756406b7, content=发展优势, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 12 14:35:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-16 1dd7d1dam20(暂无匿称)

    了解

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1897666, encodeId=ff6f189e66612, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 10 02:13:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58027, encodeId=04555802ef2, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:12:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408718, encodeId=dade1408e18a3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 14 02:13:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56950, encodeId=331d56950c9, content=为什么点进去说是没有相关资源呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cb41604567, createdName=yz115, createdTime=Wed Jan 13 16:49:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56533, encodeId=681356533da, content=学习……, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90511609422, createdName=lindaliu, createdTime=Wed Jan 13 07:32:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56511, encodeId=224a56511b3, content=为什么点不进去, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 13 00:29:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56418, encodeId=21b556418df, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jan 12 16:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56406, encodeId=222756406b7, content=发展优势, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 12 14:35:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-14 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897666, encodeId=ff6f189e66612, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 10 02:13:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58027, encodeId=04555802ef2, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:12:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408718, encodeId=dade1408e18a3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 14 02:13:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56950, encodeId=331d56950c9, content=为什么点进去说是没有相关资源呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cb41604567, createdName=yz115, createdTime=Wed Jan 13 16:49:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56533, encodeId=681356533da, content=学习……, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90511609422, createdName=lindaliu, createdTime=Wed Jan 13 07:32:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56511, encodeId=224a56511b3, content=为什么点不进去, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 13 00:29:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56418, encodeId=21b556418df, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jan 12 16:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56406, encodeId=222756406b7, content=发展优势, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 12 14:35:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-13 yz115

    为什么点进去说是没有相关资源呢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1897666, encodeId=ff6f189e66612, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 10 02:13:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58027, encodeId=04555802ef2, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:12:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408718, encodeId=dade1408e18a3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 14 02:13:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56950, encodeId=331d56950c9, content=为什么点进去说是没有相关资源呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cb41604567, createdName=yz115, createdTime=Wed Jan 13 16:49:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56533, encodeId=681356533da, content=学习……, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90511609422, createdName=lindaliu, createdTime=Wed Jan 13 07:32:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56511, encodeId=224a56511b3, content=为什么点不进去, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 13 00:29:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56418, encodeId=21b556418df, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jan 12 16:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56406, encodeId=222756406b7, content=发展优势, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 12 14:35:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-13 lindaliu

    学习……

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1897666, encodeId=ff6f189e66612, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 10 02:13:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58027, encodeId=04555802ef2, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:12:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408718, encodeId=dade1408e18a3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 14 02:13:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56950, encodeId=331d56950c9, content=为什么点进去说是没有相关资源呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cb41604567, createdName=yz115, createdTime=Wed Jan 13 16:49:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56533, encodeId=681356533da, content=学习……, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90511609422, createdName=lindaliu, createdTime=Wed Jan 13 07:32:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56511, encodeId=224a56511b3, content=为什么点不进去, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 13 00:29:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56418, encodeId=21b556418df, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jan 12 16:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56406, encodeId=222756406b7, content=发展优势, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 12 14:35:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-13 zhuzhuba1

    为什么点不进去

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1897666, encodeId=ff6f189e66612, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 10 02:13:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58027, encodeId=04555802ef2, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:12:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408718, encodeId=dade1408e18a3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 14 02:13:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56950, encodeId=331d56950c9, content=为什么点进去说是没有相关资源呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cb41604567, createdName=yz115, createdTime=Wed Jan 13 16:49:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56533, encodeId=681356533da, content=学习……, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90511609422, createdName=lindaliu, createdTime=Wed Jan 13 07:32:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56511, encodeId=224a56511b3, content=为什么点不进去, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 13 00:29:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56418, encodeId=21b556418df, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jan 12 16:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56406, encodeId=222756406b7, content=发展优势, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 12 14:35:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 dhzzm

    值得学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1897666, encodeId=ff6f189e66612, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Nov 10 02:13:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58027, encodeId=04555802ef2, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da3d1626631, createdName=1dd7d1dam20(暂无匿称), createdTime=Sat Jan 16 22:12:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408718, encodeId=dade1408e18a3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 14 02:13:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56950, encodeId=331d56950c9, content=为什么点进去说是没有相关资源呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cb41604567, createdName=yz115, createdTime=Wed Jan 13 16:49:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56533, encodeId=681356533da, content=学习……, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90511609422, createdName=lindaliu, createdTime=Wed Jan 13 07:32:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56511, encodeId=224a56511b3, content=为什么点不进去, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 13 00:29:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56418, encodeId=21b556418df, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jan 12 16:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56406, encodeId=222756406b7, content=发展优势, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 12 14:35:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 忠诚向上

    发展优势

    0

相关资讯

MedSci专访陈凯先院士:中医药送给世界的礼物--从屠呦呦教授获得诺奖说起

11月4日,上海科普大讲坛特邀我国著名药学家、中科院院士、上海市科协主席陈凯先院士,带领公众从青蒿素开始,走进中医药学的神奇世界,陈凯先院士跟我们分享《中医药送给世界的礼物》,并鼓励年轻科研工作者一定要发扬我国原创科技优势,加强中药和天然药物创新研究。 在此次分享会中,梅斯医学(MedSci)有幸采访到陈凯先院士。 MedSci:陈院士,您好,感谢您接受我们的采访,2015年10月,中国药

中医药发展进入“国际化时代”,北京打造五大中心

中医药的“治未病”观念及其在防治现代疾病方面的优势和特色,正在被越来越多的国家和医学界认可和接受。11月7日,国家中医药管理局副局长马建中在“中国中医科学院建院60周年国际学术发展大会”上表示,随着屠呦呦荣获2015年诺贝尔奖,以及国家“一带一路”战略布局的推动,“一个与现代医学相互借鉴、共同补充发展的中医药国际化时代已经到来。”世界卫生组织驻华代表施贺德在致辞中表示,传统医学用一种全面的方式

现代中医药为艾滋病治疗注入新活力

日前,在云南腾冲市召开的云南省中医药治疗艾滋病试点项目工作会上,昆明市中医药治疗艾滋病试点项目工作得到省中医药管理局充分肯定,荣获全省中医药治疗艾滋病试点项目2014年度优秀组织和优秀工作两项奖项。 昆明市中医医院主治医师陈昕说,中医药治疗艾滋病和西医有很多不同,医生了解患者感染情况后,要通过中医传统的诊脉、观色等方式,判断病人的体质。中医认为每个人都有不同的体质,需要不同的治疗方法。除了运

中国首部中医药法草案初审 中医可通过考核获医师资格

12月21日,《中医药法(草案)》首次提请十二届全国人大常委会第十八次会议审议,这标志着我国第一部中医药领域的法律进入正式立法程序。草案顺应中医药特点和发展需要,就资格准入、人才培养、中医药服务等制度作出了规定。草案规定,中医服务人员由省级中医药主管部门根据中医药技术方法的安全风险组织开展分类考核,考核合格即获得医师资格,并可以以个人开业的方式从事医疗活动。同时,草案也对现行执业医师法、医疗机构管

屠呦呦在诺奖报告会演讲:中医药学是一个伟大宝库

2015年诺贝尔生理学或医学奖得主,中国女药学家屠呦呦已经抵达瑞典并将于10日出席诺贝尔颁奖典礼。当地时间12月7日下午(北京时间7日晚),屠呦呦在卡罗琳医学院诺贝尔大厅用中文做题为《青蒿素的发现 中国传统医学对世界的礼物》的演讲,由翻译进行同声传译。屠呦呦在演讲中说:“中国医药学是一个伟大宝库,应当努力发掘,加以提高。”青蒿素正是从这一宝库中发掘出来的。通过抗疟药青蒿素的研究经历,深感中西医

中医药领域启动国家自然科学基金重大项目

16日,由成都中医药大学梁繁荣教授主持的国家自然科学基金“十二五”重大项目——“穴位的敏化研究”在成都启动,这是中医药领域首个国家自然科学基金重大项目。 据悉,该项目由成都中医药大学牵头,北京中医药大学、复旦大学、中国人民解放军第四军医大学、四川大学联合承担,是中医药领域首个获得立项资助的国家自然科学基金重大项目。项目研究目标是揭示穴位敏化在不同病症发生、发展、转归的时空动态规律,为

Baidu
map
Baidu
map
Baidu
map